Investigators retraced features contributing to Lyme disease spread by sequencing 146 Borrelia burgdorferi isolates collected in North America since the 1980s.
Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.
The firm remains on track to file for FDA clearance of its T2Bacteria panel, which its CEO called a "game changer" by mid-2017.
Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The funds, which the company said are part of a larger $9 million Series A round, will support the development of its test for early diagnosis of Lyme disease.
T2 said it's in a strong position to achieve planned portfolio milestones over the next two years, including submitting its next test for FDA clearance next year.
The deal gives Oxford access to Imugen’s Lyme disease tests as well as PCR and immunoassay tests.
A PCR-based look at pathogens and parasites in adult Ixodes ricinus ticks from France identified multiple pathogens in more than 20 percent of adult individuals tested.
RNA sequencing uncovered differentially expressed genes in individuals with Lyme disease at diagnosis, immediately after antibiotic treatment, and six months later.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.